FDA Approves Remestemcel-L: A Breakthrough Treatment for SR-aGVHD in Children
FDA Approves Remestemcel-L: A Lifesaving Therapy for SR-aGVHD The FDA has granted approval to Remestemcel-L (Ryoncil), a groundbreaking treatment for children aged 2 months and older suffering from steroid-refractory acute graft-versus-host disease (SR-aGVHD). This approval marks a significant advancement in treating a life-threatening complication of donor bone marrow transplants. Understanding SR-aGVHD SR-aGVHD occurs when donated…